Risks of Paxlovid in a Heart Transplant Recipient

Kristin Stawiarski MD, Robin Avery MD, Sara Strout PharmD, Priya Umapathi MD

1 Johns Hopkins School of Medicine, Baltimore, MD 21287

Corresponding Author: Priya Umapathi, mumapat1@jhmi.edu, Twitter: priyaumapathi

Introduction:
The burden of morbidity and mortality from SARS-CoV-2 infection is especially significant in heart transplant patients who are at higher risk for poor outcomes owing to immunosuppression, blunted response to vaccination, and multiple comorbid conditions. Over the last 3 years the therapeutic landscape for COVID-19 has evolved and our drug armamentaria continues to expand. With these advancements comes a time of great hope to mitigate significant illness from SARS – CoV – 2 infection. However, as with many emerging frontiers, the administration of novel therapeutics to a complex patient population remains challenging. We present a patient case encountered at our institution that highlights the need for increased awareness of potential toxicities and nuances in managing COVID-19 infection for a heart transplant recipient.

Case:
Recently, a 76-year-old heart transplant recipient at our center contracted mild COVID-19 infection, confirmed by PCR testing, with symptoms of sore throat and fatigue. He received his heart transplant in 2014 and was maintained on mycophenolate mofetil (500mg daily) and tacrolimus (1mg twice daily) with therapeutic range of 4-6 ng/mL. His 2-dose COVID-19 vaccination series, plus two booster doses, were completed two months prior to infection. All vaccine doses were the BNT162b2 mRNA vaccine. He was prescribed nirmatrelvir/ritonavir (Paxlovid) 300mg/100 mg twice daily under the emergency use authorization by another physician with no adjustment to his tacrolimus dose. He delayed notifying the transplant office until two days later, at which time he was instructed to discontinue nirmatrelvir-ritonavir immediately, and to present to the Emergency Department. As anticipated, his tacrolimus level returned supratherapeutic at 49 ng/mL from 5.5 ng/mL the month prior (Figure 1). He also had acute kidney injury with creatinine of 2.6 mg/dL, from baseline 1.8-2.0 mg/dL. Nirmatrelvir/ritonavir was not restarted, and he received monoclonal antibody therapy with 175mg of bebtelovimab. He had symptom resolution without the need for additional COVID specific therapies such as steroids or remdesivir. Tacrolimus was held. His additional home medications included aspirin, lisinopril, atorvastatin, icosapent ethyl, omeprazole, famotidine, semaglutide, and insulin. The tacrolimus level peaked at 54.6 ng/mL and then gradually
decreased to an acceptable range (10.5 ng/mL) with subsequent resolution of acute kidney injury over his 7-day hospitalization.

Nirmatrelvir is a SARS-CoV-2 main (M\textsuperscript{pro} or 3CL) protease inhibitor given in combination with ritonavir, which acts as a pharmacokinetic booster to increase nirmatrelvir concentrations. Preliminary outcomes of the EPIC-HR study reported an 89% reduction in the relative risk of hospitalization for unvaccinated patients treated with nirmatrelvir/ritonavir compared with placebo.\(^3\) However, ritonavir is a potent inhibitor and inducer of several cytochrome P450 enzymes, resulting in the potential for a wide range of drug interactions. Transplant recipients are particularly vulnerable due to the potent interaction with calcineurin inhibitors (CNI) and mTOR inhibitors (mTORi) due to inhibition of CYP3A and p-glycoprotein by ritonavir.\(^4\) When used in combination with ritonavir, tacrolimus dosing requirements are reduced as much as 99%, and patients often maintain therapeutic levels with low doses of tacrolimus a few times a week or less when used concurrently.\(^3\) Similar interactions with cyclosporine, everolimus, and sirolimus are expected.\(^3\) If used concurrently, holding CNI and mTORi doses should be considered while receiving nirmatrelvir/ritonavir and for 2-3 days after completing therapy unless therapeutic drug monitoring is available to guide dosing.\(^3\) Ritonavir is an irreversible CYP3A inhibitor, so return to normal drug metabolism is dependent on production of new CYP3A enzymes, with pharmacokinetic modeling suggesting return to ~80% function in 48-72 hours but that some effect may persist for at least a week.\(^3\) The effect of these interactions is difficult to manage without close therapeutic drug monitoring, which may be challenging in the outpatient setting while quarantining. There have been recommendations made regarding dose adjustment of calcineurin inhibitors (CNI) to be used in conjunction with nirmatrelvir/ritonavir, however, no definitive guidelines exist.\(^3,4\) Additionally, transplant recipients are commonly receiving medications for various comorbidities that may also need to be held or adjusted during nirmatrelvir/ritonavir therapy. One such example is atorvastatin which our patient was taking at the time of nirmatrelvir/ritonavir therapy that may have potentiated the adverse effects. Close, co-management of COVID-19 in heart transplant patients with primary care providers, pharmacists, and transplant teams is imperative.

Given the availability of other highly effective therapies such as monoclonal antibodies, these are vastly preferred for patients on immunosuppressive regimens who have issues with profound drug/drug interactions.\(^5\) It may be prudent to approach the use of nirmatrelvir/ritonavir if it is the only option available, and even then, to proceed with extreme caution and very close monitoring.

**Conclusion**

The advent of novel, COVID-19 antiviral therapy is a welcome tool against severe disease in high risk patients with increasing nation-wide use of the FDA Emergency Use Authorization (EUA) for two oral antivirals - Nirmatrelvir/Ritonavir and Molnupiravir for treatment of COVID-19. Transplant recipients are among the group eligible for this therapy and we present a case that highlights some cautions to be considered when treating these patients. Given the concerns for potent drug-drug interaction between the oral antivirals and CNI’s, the American Society for
Transplantation recommends that providers consider other therapies available for early disease that are shown to reduce progression to severe disease such as monoclonal antibodies or early treatment with intravenous remdesivir. Recommendations are suggested related to mitigating the drug-drug interaction with CNI’s but may prove cumbersome/infeasible in real-world clinical situations. Nirmatrelvir/ritonavir is undoubtedly very useful in mitigating the severity of COVID-19 for patients who have risk factors. However, in the transplant population it is reasonable to consider as first line other highly effective therapies such as monoclonal antibodies (notably bebtelovimab at the time of this writing) that may obviate the need for antivirals and the drug-drug interactions that arise.

Acknowledgements: No conflict of interest for any authors who participated in this manuscript. No funding sources supported this work.

References:

Figure 1. Trends of tacrolimus and creatinine levels from prior to COVID-19 infection until discharge. The patient’s individual tacrolimus target trough level is 4-6 ng/mL.